Back to top
more

4D Molecular Therapeutics (FDMT)

(Real Time Quote from BATS)

$15.59 USD

15.59
207,042

+0.20 (1.30%)

Updated Aug 25, 2026 11:44 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (150 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of +0.98% and -91.09%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

How Much Upside is Left in 4D Molecular Therapeutics (FDMT)? Wall Street Analysts Think 171.74%

by Zacks Equity Research

The consensus price target hints at a 171.7% upside potential for 4D Molecular Therapeutics (FDMT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Wall Street Analysts See a 208.52% Upside in 4D Molecular Therapeutics (FDMT): Can the Stock Really Move This High?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 208.5% in 4D Molecular Therapeutics (FDMT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

SNY's Gene Therapy Candidate for Eye Disease Gets FDA Fast Track Tag

by Zacks Equity Research

Sanofi's gene therapy SAR402663 for wet AMD earns FDA fast track status, aiming to speed up development and reduce treatment burden.

Zacks Equity Research

4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of -11.36% and -98.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of -2.38% and 98.70%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of -17.91% and 99.76%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of -11.11% and 8.50%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 0% and 9.86%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Nektar (NKTR) delivered earnings and revenue surprises of 21.74% and 55.24%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?